Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | SQLE | Q14534 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701611 | 1.00 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL23452103 | 1.00 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL2780073 | 1.00 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL1219115 | 0.98 | KMT2A (0.68) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10815851 | 0.98 | KMT2A (0.68) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL1219116 | 0.98 | KMT2A (0.68) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL8850002 | 0.86 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL11290924 | 0.86 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL23581543 | 0.86 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL8013144 | 0.85 | KMT2A (1.00) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171489-A1 | SYNTHESIS OF CHROMANOL AND 2-METHYL-1,4-NAPHTHOQUINONE DERIVATIVES | BASF SE (DE) | 2021-06-10 | — | — | US | disclosed |
| CN-112888678-A | Synthesis of chromanol and 2-methyl-1, 4-naphthoquinone derivatives | 巴斯夫欧洲公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-2556043-B1 | NEW POLYTERPENE TYPE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND TOPICAL USES THEREOF | SEDERMA SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2556043-A2 | NEW POLYTERPENE TYPE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND TOPICAL USES THEREOF | Sederma (FR) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011125040-A2 | NEW POLYTERPENE TYPE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND TOPICAL USES THEREOF | SEDERMA (FR) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171489-A1 | SYNTHESIS OF CHROMANOL AND 2-METHYL-1,4-NAPHTHOQUINONE DERIVATIVES | CYP4B1, CYP2J2, CYP1A2 | KMT2A 461/4885ALOX15 2321/4885MAPT 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.